FDA Says No Way To Food Companies Wanting To Get On The CBD Gravy Train
As several major food makers are champing at the bit to cash in on the CBD food and drinks craze, it seems the FDA is still not down with the program.
Analysts Put Alnylam On Upside Catalyst Watch Ahead Of Upcoming Data From Lead Program
RBC Capital Markets raised the price target on Alnylam Pharmaceuticals Inc (NASDAQ:ALNY) from $225 to $250. The analyst says that the company…
Satsuma Pharma Shares Are Gaining After Encouraging Update From Migraine Candidate
Satsuma Pharmaceuticals Inc (NASDAQ:STSA) announced favorable safety, tolerability, and efficacy results from its recent analysis of the ongoing STS101 ASCEND…
Merck To Start New Islatravir HIV Trials With Lower Dose After FDA Hold
Merck & Co Inc (NYSE:MRK) will initiate a new Phase 3 program with once-daily islatravir to treat people with HIV-1 infection. …
United Therapeutics Stops Late-Stage Tyvaso Study In Lung Disease
United Therapeutics Corp (NASDAQ:UTHR) has terminated the Phase 3 PERFECT study evaluating Tyvaso (treprostinil) Inhalation Solution for pulmonary hypertension associated with…
‘New York City Lifting Covid-19 Vaccine Mandate For Private Sector’ – Abc7NY
https://abc7ny.com/nyc-covid-mask-mandate-new-york-statistics/12242966/?ex_cid=TA_WABC_TW&taid=6329c8841c8e330001002b70&utm_campaign=trueAnthem:+New+Content+(Feed)&utm_medium=trueAnthem&utm_source
AstraZeneca’s COVID-19 Antibody Treatment Scores Approval In Europe
The European Commission has approved AstraZeneca plc’s (NASDAQ:AZN) Evusheld (tixagevimab and cilgavimab, formerly AZD7442), a long-acting antibody combination as COVID-19 treatment…